Skip to main content
Premium Trial:

Request an Annual Quote

Cepheid Xpert MTB/RIF Ultra

Cepheid, Rutgers New Jersey Medical School and FIND launched the Xpert MTB/RIF Ultra test for diagnosing tuberculosis and resistance to the antibiotic rifampicin. The test is the second generation of Cepheid's Xpert MTB/RIF test, which was launched in 2010. The Ultra was redesigned to increase analytical sensitivity more than tenfold and to improve the detection of mutations associated with rifampin resistance, FIND said.

The World Health Organization recommends the new test be used as an alternative to the older test in all settings, but a WHO expert group also noted that because of the increased sensitivity, use of the Ultra can result in higher numbers of false positives, compared to Expert MTB/RIF. As a result, the group said more discussion is needed on implementing the new test and balancing increased sensitivity with decreased specificity in different settings.

The Ultra was developed by Cepheid in collaboration with Rutgers. Additional support was provided by the US National Institute of Allergy and Infectious Diseases, and FIND. The governments of Australia, the Netherlands, and the UK also provided funding. 

The Scan

Boosters Chasing Variants

The New York Times reports that an FDA advisory panel is to weigh updated booster vaccines for COVID-19.

Not Yet

The World Health Organization says monkeypox is not yet a global emergency, the Washington Post reports.

More Proposed for Federal Research

Science reports that US House of Representatives panels are seeking to increase federal research funding.

PLOS Papers on Breast Cancer Metastasis, Left-Sided Cardiac Defects, SARS-CoV-2 Monitoring

In PLOS this week: link between breast cancer metastasis and CLIC4, sequencing analysis of left-sided cardiac defects, and more.